Fig. 1From: A phase I–II controlled randomized trial using a promising novel cell-free formulation for articular cartilage regeneration as treatment of severe osteoarthritis of the kneeClinical progression of patients over 12 months, according to the different scales for evaluating osteoarthritis. a Percentages of patients with successful treatment over time, according to the different evaluation scales are shown (scores: WOMAC ≤ 29 at 3 and 6 months and ≤ 16 points at 12 months, Rasmussen clinical score ≥ 24, RAPID3 ≤ 2). None of the patients in the NSAID group had treatment success. At month 6, 75% of the patients treated with BIOF2 had treatment success, according to the WOMAC scale. At month 12, the treatments with BIOF2 and arthroplasty showed no statistically significant differences, according to all the scales. b WOMAC subscales for pain, stiffness, and physical function. The group treated exclusively with NSAIDs had no changes over time. The treatments with BIOF2 and arthroplasty produced significant changes over time in all the subscales (one-way ANOVA test P < 0.05, for both groups). Mean and standard error were plottedBack to article page